Literature DB >> 1632943

The pharmacological effect of citalopram residues in the (S)-(+)-enantiomer.

J Hyttel1, K P Bøgesø, J Perregaard, C Sánchez.   

Abstract

The enantiomers of citalopram and N-demethylcitalopram have been investigated. Based on the inhibition of 5-HT uptake in vitro and the potentiation of 1-5-HTP in vivo the pharmacological activity resides in the (+)-enantiomers (the eutomers*) with the 1-(S) absolute configuration. In the 5-HT uptake test eudismic ratios of 167 and 6.6 are obtained for the enantiomers of citalopram and N-demethylcitalopram, respectively. The pharmacological profile of the eutomers of citalopram and N-demethylcitalopram very much resembles the profile of the respective racemates.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1632943     DOI: 10.1007/bf01244820

Source DB:  PubMed          Journal:  J Neural Transm Gen Sect


  4 in total

1.  Inhibition of [3H]dopamine accumulation in rat striatal synaptosomes by psychotropic drugs.

Authors:  J Hyttel
Journal:  Biochem Pharmacol       Date:  1978-04-01       Impact factor: 5.858

Review 2.  Citalopram. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depressive illness.

Authors:  R J Milne; K L Goa
Journal:  Drugs       Date:  1991-03       Impact factor: 9.546

3.  Effect of a specific 5-HT uptake inhibitor, citalopram (Lu 10-171), on 3H-5-HT uptake in rat brain synaptosomes in vitro.

Authors:  J Hyttel
Journal:  Psychopharmacology (Berl)       Date:  1978-12-15       Impact factor: 4.530

Review 4.  Citalopram--pharmacological profile of a specific serotonin uptake inhibitor with antidepressant activity.

Authors:  J Hyttel
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  1982       Impact factor: 5.067

  4 in total
  53 in total

Review 1.  Metabolism and pharmacokinetics of selective serotonin reuptake inhibitors.

Authors:  C L DeVane
Journal:  Cell Mol Neurobiol       Date:  1999-08       Impact factor: 5.046

2.  Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers.

Authors:  Adriana Rocha; Eduardo B Coelho; Stefânia A Sampaio; Vera L Lanchote
Journal:  Br J Clin Pharmacol       Date:  2010-07       Impact factor: 4.335

3.  Newer antidepressants in the primary care setting.

Authors:  J Sloan Manning
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2004

Review 4.  The impact of the CYP2D6-polymorphism on dose recommendations for current antidepressants.

Authors:  Norbert Thuerauf; Jens Lunkenheimer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2006-08       Impact factor: 5.270

5.  Predicting Escitalopram Exposure to Breastfeeding Infants: Integrating Analytical and In Silico Techniques.

Authors:  Sarah R Delaney; Paul R V Malik; Cristiana Stefan; Andrea N Edginton; David A Colantonio; Shinya Ito
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447

6.  Systems genetics analysis of pharmacogenomics variation during antidepressant treatment.

Authors:  M B Madsen; L J A Kogelman; H N Kadarmideen; H B Rasmussen
Journal:  Pharmacogenomics J       Date:  2016-10-18       Impact factor: 3.550

7.  Molecular determinants for selective recognition of antidepressants in the human serotonin and norepinephrine transporters.

Authors:  Jacob Andersen; Nicolai Stuhr-Hansen; Linda Zachariassen; Søren Toubro; Stinna M R Hansen; Jonas N N Eildal; Andrew D Bond; Klaus P Bøgesø; Benny Bang-Andersen; Anders S Kristensen; Kristian Strømgaard
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-05       Impact factor: 11.205

8.  Citalopram and escitalopram plasma drug and metabolite concentrations: genome-wide associations.

Authors:  Yuan Ji; Daniel J Schaid; Zeruesenay Desta; Michiaki Kubo; Anthony J Batzler; Karen Snyder; Taisei Mushiroda; Naoyuki Kamatani; Evan Ogburn; Daniel Hall-Flavin; David Flockhart; Yusuke Nakamura; David A Mrazek; Richard M Weinshilboum
Journal:  Br J Clin Pharmacol       Date:  2014-08       Impact factor: 4.335

Review 9.  The Role of Metabolites of Antidepressants in the Treatment of Depression.

Authors:  M V Rudorfer; W Z Potter
Journal:  CNS Drugs       Date:  1997-04       Impact factor: 5.749

Review 10.  Trends in the development of new antidepressants. Is there a light at the end of the tunnel?

Authors:  Pal Pacher; Valeria Kecskemeti
Journal:  Curr Med Chem       Date:  2004-04       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.